Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life

Author(s): Suman Kumar Ray and Sukhes Mukherjee*

Volume 16, Issue 1, 2022

Published on: 03 March, 2022

Page: [2 - 5] Pages: 4

DOI: 10.2174/1872208315666211209094457

Abstract

Coronavirus Disease 2019 (COVID-19) is caused by a new strain of coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV- 2). It is the most challenging pandemic of this century. The growing COVID-19 pandemic has triggered extraordinary efforts to restrict the virus in numerous ways, owing to the emergence of SARS-CoV-2. Immunotherapy, which includes artificially stimulating the immune system to generate an immunological response, is regarded as an effective strategy for preventing and treating several infectious illnesses and malignancies. Given the pandemic's high fatality rate and quick expansion, an effective vaccination is urgently needed to keep it under control. The basic goal of all COVID-19 vaccine programs is to develop a vaccine that causes the generation of surface protein neutralizing antibodies in subjects. The epitope discovery for the SARS-CoV-2 vaccine candidates is likewise made using an immuno-informatics methodology. It can be used to find the epitopes in viral proteins important for cytotoxic T cells and B cells. A safe and effective COVID-19 vaccine that can elicit the necessary immune response is necessary to end the epidemic. The global search for a safe and effective COVID-19 vaccine is yielding results. More than a dozen vaccines have already been approved around the world, with many more in the clinical trials. Patents can cover the underlying technology used to generate a vaccine, whereas trade secrets can cover manufacturing methods and procedures.

Keywords: COVID-19, SARS-CoV-2, pandemic, immune response, vaccine, patent.

« Previous Next »
Graphical Abstract

[1]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3): 105924.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[2]
Zoumpourlis V, Goulielmaki M, Rizos E, Baliou S, Spandidos DA. The COVID-19 pandemic as a scientific and social challenge in the 21st century. Mol Med Rep 2020; 22(4): 3035-48.
[http://dx.doi.org/10.3892/mmr.2020.11393] [PMID: 32945405]
[3]
Ray SK, Mukherjee S. Understanding the role of corona virus based on current scientific evidence - a review with emerging importance in pandemic. Recent Pat Antiinfect Drug Discov 2020; 15(2): 89-103.
[http://dx.doi.org/10.2174/1574891X15999200918144833] [PMID: 32957894]
[4]
Mallah SI, Ghorab OK, Al-Salmi S, et al. COVID-19: Breaking down a global health crisis. Ann Clin Microbiol Antimicrob 2020; 20(1): 35.
[5]
Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: From SARS and MERS to COVID-19. J Biomed Sci 2020; 27(1): 104.
[http://dx.doi.org/10.1186/s12929-020-00695-2] [PMID: 33341119]
[6]
Mellet J, Pepper MSA. A COVID-19 vaccine: Big strides come with big challenges. Vaccines (Basel) 2021; 9(1): 39.
[http://dx.doi.org/10.3390/vaccines9010039] [PMID: 33440895]
[7]
Corbett KS, Edwards DK, Leist SR, et al. SARS- CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020; 586(7830): 567-71.
[http://dx.doi.org/10.1038/s41586-020-2622-0] [PMID: 32756549]
[8]
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 2020; 383(20): 1920-31.
[http://dx.doi.org/10.1056/NEJMoa2022483] [PMID: 32663912]
[9]
van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020; 586(7830): 578-82.
[http://dx.doi.org/10.1038/s41586-020-2608-y] [PMID: 32731258]
[10]
Su S, Du L, Jiang S. Learning from the past: Development of safe and effective COVID-19 vaccines. Nat Rev Microbiol 2021; 19(3): 211-9.
[http://dx.doi.org/10.1038/s41579-020-00462-y] [PMID: 33067570]
[11]
Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021; 21(2): 73-82.
[http://dx.doi.org/10.1038/s41577-020-00480-0] [PMID: 33340022]
[12]
Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 2020; 5(1): 237.
[http://dx.doi.org/10.1038/s41392-020-00352-y] [PMID: 33051445]
[13]
Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 2020; 5(10): 1185-91.
[http://dx.doi.org/10.1038/s41564-020-00789-5] [PMID: 32908214]
[14]
Forni G, Mantovani A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ 2021; 28(2): 626-39.
[http://dx.doi.org/10.1038/s41418-020-00720-9] [PMID: 33479399]
[15]
Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396(10255): 887-97.
[http://dx.doi.org/10.1016/S0140-6736(20)31866-3] [PMID: 32896291]
[16]
Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel) 2021; 9(3): 238.
[http://dx.doi.org/10.3390/vaccines9030238] [PMID: 33801831]
[17]
Rubin R. COVID-19 vaccines vs variants-determining how much immunity is enough. JAMA 2021; 325(13): 1241-3.
[http://dx.doi.org/10.1001/jama.2021.3370] [PMID: 33729423]
[18]
Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy 2021; 125(5): 553-67.
[http://dx.doi.org/10.1016/j.healthpol.2021.03.013] [PMID: 33820678]
[19]
Gilbert SC, Lambe T. Recombinant protein vaccines against SARS-CoV-2. Lancet Infect Dis 2021; S1473-3099(21): 227-9.
[20]
Gaviria M, Kilic B. A network analysis of COVID-19 mRNA vaccine patents. Nat Biotechnol 2021; 39(5): 546-8.
[http://dx.doi.org/10.1038/s41587-021-00912-9] [PMID: 33981074]

Rights & Permissions Print Cite
Article Metrics
10
1
© 2024 Bentham Science Publishers | Privacy Policy